quinuclidines has been researched along with Pulmonary Disease, Chronic Obstructive in 136 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (1.47) | 29.6817 |
| 2010's | 99 (72.79) | 24.3611 |
| 2020's | 35 (25.74) | 2.80 |
| Authors | Studies |
|---|---|
| Bjermer, L; Boucot, I; Compton, C; Ismaila, AS; Jones, PW; Kendall, R; Kerwin, E; Lipson, DA; Maltais, F; Martin, A; Risebrough, NA; Shah, D; Shukla, S; Tombs, L; Vogelmeier, CF | 1 |
| Abbott, T; Balmaceda, C; Espinoza, MA; Peters, A | 1 |
| Bogart, M; Duh, MS; Germain, G; Jung, Y; Laliberté, F; MacKnight, SD; Mannino, D; Stiegler, M; Wu, B | 1 |
| Calzetta, L; Cazzola, M; Matera, MG; Ora, J; Rogliani, P | 1 |
| Chan, MC; Chen, NH; Cheng, SL; Hsieh, MJ; Hsu, WH; Kuo, PH; Lin, MS; Liu, CL; Liu, SF; Tao, CW; Tsai, YH; Wei, YF; Wu, YK; Yang, TM | 1 |
| Agarwal, J; Compton, C; Czira, A; Dong, X; Duarte, M; Haeussler, K; Halpin, DMG; Ismaila, AS; Malmenäs, M; Nassim, M; Shen, Y; Tongbram, V; Vogelmeier, CF; Živković-Gojović, M | 1 |
| Baio, G; Criner, GJ; Gabrio, A; Gunsoy, NB; Halpin, DMG; Han, MK; Ismaila, AS; Lipson, DA; Martin, A; Martin, N; Martinez, FJ; Paly, VF; Risebrough, N; Singh, D; Wise, RA | 1 |
| Bolotova, EV; Dudnikova, AV; Shulzhenko, LV | 1 |
| Beeh, KM; Compton, C; Halpin, DMG; Ismaila, AS; Jones, PW; Kendall, R; Kocks, JWH; Martin, A; Midwinter, D; Risebrough, NA; Shah, D; Shukla, S | 1 |
| Bardsley, S; Berkman, N; Criner, GJ; Halpin, DMG; Han, MK; Hanania, NA; Hill, D; Lange, P; Lipson, DA; Martinez, FJ; Midwinter, D; Siler, TM; Singh, D; van Zyl-Smit, RN; Wise, RA | 1 |
| Bengtson, LGS; Bogart, M; Bunner, SH; Hanania, NA; Ismaila, AS | 1 |
| Darken, P; Marshall, J; Ouwens, M; Sharma, A; Singh, B; Tansey-Dwyer, D | 1 |
| Compton, C; Haeussler, K; Halpin, DMG; Han, MK; Ismaila, AS; Malmenäs, M; Sharma, R; Vogelmeier, CF | 1 |
| Bengtson, LGS; Buysman, EK; Clark, B; Ferguson, GT; Palli, S; Sargent, A; Sethi, S; Shaikh, A | 1 |
| Banks, V; Castillo, CM; Compton, C; Czira, A; Herth, F; Ismaila, AS; Quint, JK; Requena, G; Rothnie, KJ; Tritton, T; Wild, R; Wood, R; Yeap, J | 2 |
| Abbott, CB; Bangalore, M; Bogart, M; DiRocco, K; McMorrow, D; Packnett, ER | 1 |
| Bjermer, L; Boucot, IH; Compton, C; Jones, PW; Kerwin, EM; Lipson, DA; Maltais, F; Naya, IP; Tombs, L; Vahdati-Bolouri, M; Vogelmeier, CF; Watkins, ML | 1 |
| Criner, G; Dransfield, M; Goodall, EC; Halpin, DM; Han, MK; Ismaila, AS; Lomas, DA; Martin, A; Ndirangu, K; Risebrough, N; Schroeder, M; Shah, D | 1 |
| Clifton, CS; Gross, AS; Hashimoto, K; Ishii, T; Jones, CE; Kato, M; Kilbride, S; Lipson, DA; Nezu, Y; Tomii, K | 1 |
| Vestbo, J | 1 |
| Suissa, S | 1 |
| Dransfield, MT; Han, MK; Lipson, DA | 1 |
| Bogart, MR; Coutinho, AD; Hopson, SD; Shih, HC; Stanford, RH | 1 |
| Criner, G; Day, NC; Dransfield, M; Halpin, DMG; Han, MK; Jones, CE; Kaisermann, MC; Kilbride, S; Kumar, S; Lange, P; Lipson, DA; Lomas, DA; Martin, N; Martinez, FJ; Singh, D; Wise, R | 1 |
| Beier, J; Friedrich, FW; Plate, T | 1 |
| Criner, GJ; Dransfield, MT; Halpin, DMG; Han, MK; Jones, CE; Kaisermann, MC; Kilbride, S; Lange, P; Lipson, DA; Lomas, DA; Martinez, FJ; Pascoe, S; Singh, D; Tabberer, M; Wise, RA | 1 |
| Criner, GJ; Dransfield, MT; Halpin, DMG; Han, MK; Hanania, NA; Jones, CE; Kilbride, S; Lima, R; Lipson, DA; Lomas, DA; Mannino, DM; Martin, N; Martinez, FJ; Singh, D; Wise, RA | 1 |
| Elliott, C; Essoi, B; Goolsby Hunter, A; Hahn, B; Moretz, C; Ray, R; White, J | 1 |
| Hanada, S; Kunita, Y; Muraki, M; Sawaguchi, H; Shirahase, K; Tohda, Y; Yamazaki, R | 1 |
| Han, MK; Lipson, DA; Martinez, FJ; Wise, R | 1 |
| Fowler, A; Lee, LA; Peachey, G; Sule, N; Yang, S | 1 |
| Cheng, SH; Hsu, YJ; Huang, YL; Lai, JH; Lin, CW; Liou, JT; Pan, HY; Tsai, CL; Wang, MT | 1 |
| Boucot, IH; Caveney, S; Crim, C; Hanania, NA; Lettis, S; Mannino, DM; Patel, H; Soule, T; Tombs, L | 1 |
| Bjermer, L; Boucot, IH; Compton, C; Jones, PW; Kerwin, EM; Lipson, DA; Maltais, F; Naya, IP; Tombs, L; Vogelmeier, CF | 1 |
| Duh, MS; Germain, G; Hahn, B; Laliberté, F; Mahendran, M; Moretz, C; Ray, R; Shen, Q; Slade, D | 1 |
| Bjermer, LH; Boucot, IH; Compton, C; Jones, PW; Kerwin, EM; Lipson, DA; Maltais, F; Tombs, L; Vogelmeier, CF | 1 |
| Barnacle, H; Birk, R; Brealey, N; Lipson, DA; Locantore, N; Lomas, DA; Ludwig-Sengpiel, A; Mohindra, R; Pascoe, SJ; Tabberer, M; Zhu, CQ | 1 |
| Coleman, A; Earnshaw, SR; McDade, CL; Patel, JG; Stanford, RH; Wilson, MR | 1 |
| Htet, A; Moe, S; Ni, H | 1 |
| Collison, K; Kerwin, E; Lee, L; Nelsen, L; Pascoe, S; Wu, W; Yang, S | 1 |
| Elbehairy, AF; Faisal, A; Neder, JA; O'Donnell, DE; Webb, KA | 1 |
| Ayers, T; Banerji, D; Ferguson, GT; Fogel, R; Goodin, T; Kerwin, E; Maitra, S; Sanjar, S; Sen, B; Yadao, A | 1 |
| Deas, SD; Huprikar, N | 1 |
| Antohe, I; Antoniu, SA; Gavrilovici, C | 1 |
| Birk, R; Brealey, N; Lipson, DA; Locantore, N; Lomas, DA; Pascoe, S; Tabberer, M; Zhu, CQ | 1 |
| Birk, R; Brealey, N; Bremner, PR; Ismaila, AS; Lipson, DA; Zhu, CQ | 1 |
| Crisafulli, E; Torres, A | 1 |
| Barnhart, F; Brealey, N; Brooks, J; Criner, GJ; Day, NC; Dransfield, MT; Halpin, DMG; Han, MK; Jones, CE; Kilbride, S; Lange, P; Lipson, DA; Lomas, DA; Martinez, FJ; Pascoe, SJ; Singh, D; Tabberer, M; Wise, RA | 1 |
| Barnacle, H; Beerahee, M; Birk, R; Brealey, N; Lipson, DA; Mehta, R; Pefani, E; Zhu, CQ | 1 |
| Blauer-Peterson, C; Buikema, AR; Hahn, B; Hull, M; Ray, R; Stanford, RH | 1 |
| Asmus, MJ; Boucot, I; Cichoż-Lach, H; Compton, C; Fedele, L; Gabel, K; Grywalska, E; Haggerty, N; Hoddy, KK; Imbert, D; Jarjayes, O; Kowalik, A; Kroeger, CM; Lipson, DA; Michalak, A; Mielnik, M; Molloy, JK; Naya, I; Panda, S; Philouze, C; Ray, R; Roliński, J; Song, J; Thomas, F; Tombs, L; Trepanowski, JF; Varady, KA | 1 |
| Steurer, J | 2 |
| Compton, C; Lipson, DA; Naya, IP; Tombs, L | 1 |
| Alcázar-Navarrete, B; Asukai, Y; Driessen, MT; García-Río, F; Miravitlles, M; Naya, IP; Risebrough, NA; Seewoodharry Buguth, B; Vallejo-Aparicio, LA; Whalen, J | 1 |
| Baker, T; Briggs, A; Driessen, M; Ismaila, AS; Naya, I; Risebrough, N; Shah, D | 1 |
| Corhay, JL | 1 |
| Lad, R; Rhee, CK; Yoshisue, H | 1 |
| Fujimura, M; Hara, J; Ishii, N; Ishiura, Y; Kasahara, K; Nomura, S; Ohkura, N; Shimizu, T; Tamaki, T | 1 |
| Albertson, TE; Bowman, WS; Godbout, RM; Harper, RW; Murin, S | 1 |
| Barnes, N; Brusselle, G; Compton, C; Criner, GJ; Dransfield, MT; Halpin, DMG; Han, MK; Hartley, B; Lange, P; Lettis, S; Lipson, DA; Lomas, DA; Martinez, FJ; Papi, A; Pascoe, S; Roche, N; Singh, D; van der Valk, RJP; Wise, R | 1 |
| Birk, R; Farrell, C; Hayes, S; Lipson, DA; Mehta, R; Okour, M | 1 |
| Al Masri, S; Ramadan, WH; Rizk, J | 1 |
| Crater, G; Hughes, S; Kelleher, D; Mehta, R; Preece, A | 1 |
| Church, A; Donohue, JF; Kalberg, C; Kilbride, S; Maleki-Yazdi, MR; Mehta, R | 1 |
| Church, A; Mehta, R; Richard, N; Trivedi, R | 1 |
| Edin, A; Feldman, GJ | 1 |
| Cazzola, M; Matera, MG; Segreti, A | 1 |
| Celli, B; Church, A; Crater, G; Kalberg, CJ; Kilbride, S; Mehta, R; Tabberer, M | 1 |
| Beerahee, M; Brooks, J; Church, A; Mehta, R; Shah, P | 1 |
| Traynor, K | 1 |
| Hair, P; Scott, LJ | 1 |
| Bengtsson, T; Jorup, C; Sjöbring, U; Strandgården, K | 1 |
| Gras, J | 1 |
| Beerahee, M; Church, A; Goyal, N; Kalberg, C; Kilbride, S; Mehta, R | 1 |
| Banerji, D; Bateman, ED; Mahler, DA; Patalano, F; Vogelmeier, CF; Wedzicha, JA | 1 |
| Anzueto, A; Church, A; Crater, G; Decramer, M; Harris, S; Kaelin, T; Kerwin, E; Richard, N; Tabberer, M | 1 |
| Sin, DD | 1 |
| Beerahee, M; Church, A; Donohue, JF; Gunawan, R; Kalberg, C; Mehta, R; Shah, P | 1 |
| Kelly, E | 1 |
| Brooks, J; Church, A; Donohue, JF; Niewoehner, D; O'Dell, D | 1 |
| Malerba, M; Morjaria, JB; Radaeli, A | 1 |
| Aronow, WS; Asija, A; Manickam, R | 1 |
| Calzetta, L; Cazzola, M; Rogliani, P; Segreti, A | 1 |
| Cazzola, M; Matera, MG; Rinaldi, B; Rogliani, P | 1 |
| Blair, HA; Deeks, ED | 1 |
| Church, A; Crater, G; Donald, AC; Goh, AH; Maltais, F; Riley, JH; Singh, S | 1 |
| Church, A; Kaelin, T; Maleki-Yazdi, MR; Richard, N; Zvarich, M | 1 |
| Davidson, JF; Donohue, JF; Ohar, JA | 1 |
| Neffen, H; Rodrigo, GJ | 1 |
| Dong, K; Gross, A; Hu, C; Jia, J; Luo, L; Mehta, R; Peng, J; Ren, Y; Wu, K; Yu, H | 1 |
| Fath, R | 1 |
| Ali, R; Church, A; Donald, A; Kerwin, E; Siler, TM; Sousa, AR | 1 |
| Nagy, LB | 1 |
| Church, A; Hardaker, L; Singh, D; Worsley, S; Zhu, CQ | 1 |
| Barnes, NC; Brooks, J; Iqbal, A | 1 |
| Church, A; Goh, AH; Newlands, A; Zheng, J; Zhong, N | 1 |
| Charles, S; Gillett, B; Hamilton, M; Leggett, R; Pang, C; Prime, D | 1 |
| Brooks, J; Church, A; Kerwin, E; Siler, TM; Singletary, K | 1 |
| Huisman, EL; Ismaila, AS; Karabis, A; Punekar, YS | 1 |
| Stanbrook, MB | 1 |
| Green, M; Mehta, R; Patel, B; Wagg, J | 1 |
| Donohue, JF; Gao, J; Pleasants, RA; Tang, H; Wang, T | 1 |
| Hashimoto, K; Mihara, K; Soutome, T; Tohda, Y; Yamagata, E | 1 |
| Melani, AS; Sestini, P | 1 |
| Church, A; Donohue, JF; Kilbride, S; Munzu, C; Singh, D | 1 |
| Carcedo, D; Gáldiz, JB; Garcia-Rio, F; Huerta, A; Miravitlles, M; Villacampa, A | 1 |
| Popova, EN | 1 |
| Fahy, WA; Galkin, D; Kalberg, C; Newlands, A; O'Dell, D | 1 |
| Church, A; Fahy, WA; Feldman, G; Khindri, S; Maltais, F; Trivedi, R; Vahdati-Bolouri, M | 1 |
| Brooks, J; Church, A; Condreay, L; Ghosh, S; Harris, E; Huang, L; Riley, JH | 1 |
| Kuwahira, I | 1 |
| Church, A; Donald, AC; Fahy, WA; O'Dell, D; Siler, TM | 1 |
| Church, A; Fahy, WA; Punekar, YS; Riley, JH; Sousa, AR; Zhu, CQ | 1 |
| Barnacle, H; Barnes, N; Brealey, N; Dransfield, MT; Lipson, DA; Locantore, N; Mohindra, R; Pascoe, SJ; Pavord, I | 1 |
| Fahy, WA; Iqbal, A; Maleki-Yazdi, MR; Naya, I; Singh, D; Tombs, L | 1 |
| Jiang, SJ; Liu, Y; Wang, L; Zhai, CJ | 1 |
| Church, A; Donald, A; Harris, SS; Richard, N; Riley, JH; Tabberer, M | 1 |
| Anzueto, A; Fahy, WA; Maleki-Yazdi, MR; Naya, I; Singh, D; Tombs, L | 1 |
| Kardos, P; Müllerová, H; Newby, DE; Román-Rodríguez, M; Singh, D; Worsley, S | 1 |
| Durigan, RC; Niedermier, V | 1 |
| Lal, C; Strange, C | 1 |
| Albertí, J; Antón, F; Beleta, J; Buil, MA; Cárdenas, A; Casals, G; Castro, J; Crespo, MI; Doménech, T; Espinosa, S; Fernández, D; Ferrer, M; Gavaldà, A; González, M; Huerta, JM; López, M; Miralpeix, M; Monleón, JM; Prat, M; Ramos, I; Ryder, H; Segarra, V; Sentellas, S; Tort, L; Vilella, D | 1 |
| Bowers, K; Chevalier, E; Donald, DK; Edwards, H; Escott, KJ; Ford, R; Grime, K; Mete, A; Millichip, I; Russell, V; Teobald, B | 1 |
| Anzueto, A; Brooks, J; Crater, G; Donohue, JF; Kalberg, C; Mehta, R | 1 |
| Brooks, J; Crater, G; Feldman, G; Mehta, R; Walker, RR | 1 |
| Brooks, J; Crater, G; Decramer, M; Feldman, G; Harris, S; Maltais, F; Mehta, R | 1 |
| Bengtsson, T; Bjermer, L; Jorup, C; Lötvall, J | 1 |
| Liao, Z; Tong, RS; Xiao, HT | 1 |
| Cahn, A; Crater, G; Kelleher, D; Mehta, R; Pouliquen, IJ; Preece, A; Tal-Singer, R | 1 |
| Christophe, B; Gillard, M; Guyaux, M; Jadot, S; Lo Brutto, P; Provins, L; Quéré, L; Starck, JP; Talaga, P | 1 |
31 review(s) available for quinuclidines and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Dyspnea; Forced Expiratory Volume; Glycopyrrolate; Humans; Muscarinic Antagonists; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Salmeterol Xinafoate; Tiotropium Bromide; Treatment Outcome | 2022 |
Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis".
Topics: Administration, Inhalation; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Fluticasone; Humans; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2023 |
A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis".
Topics: Administration, Inhalation; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Fluticasone; Humans; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2023 |
Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
Topics: Anti-Bacterial Agents; Bromides; Disease Progression; Female; Forced Expiratory Volume; Hospitalization; Humans; Male; Middle Aged; Numbers Needed To Treat; Placebos; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Smoking; Steroids | 2017 |
Dual bronchodilator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and Safety of fixed dose combination treatments in the setting of recent guideline updates.
Topics: Administration, Inhalation; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Delayed-Action Preparations; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Tiotropium Bromide; Tropanes | 2018 |
COPD 2017: A Year in Review.
Topics: Androstadienes; Antibodies, Monoclonal, Humanized; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Common Cold; Disease Progression; Drug Combinations; Eosinophils; Glucocorticoids; Haemophilus Infections; Humans; Interleukin-5; Moraxellaceae Infections; Muscarinic Antagonists; Noninvasive Ventilation; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Seasons; Severity of Illness Index; Tiotropium Bromide | 2018 |
Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Asian People; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Tiotropium Bromide; Treatment Outcome; Tropanes | 2019 |
Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Dry Powder Inhalers; Evidence-Based Medicine; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Recovery of Function; Treatment Outcome | 2019 |
Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dry Powder Inhalers; Forced Expiratory Volume; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Respiratory Function Tests | 2019 |
The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
Topics: Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Dose-Response Relationship, Drug; Drug Combinations; Humans; Muscarinic Antagonists; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Severity of Illness Index | 2013 |
New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Delayed-Action Preparations; Drug Combinations; Forced Expiratory Volume; Humans; Muscarinic Antagonists; Outcome Assessment, Health Care; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2013 |
Anoro Ellipta: an inhaled umeclidinium/vilanterol combination for COPD.
Topics: Administration, Inhalation; Animals; Benzyl Alcohols; Chlorobenzenes; Cholinergic Antagonists; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic | 2014 |
Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Disease Management; Disease Progression; Drug Combinations; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2014 |
Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2014 |
Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol.
Topics: Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Recovery of Function; Time Factors; Treatment Outcome | 2014 |
Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use.
Topics: Administration, Inhalation; Animals; Drug Administration Schedule; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Risk Assessment; Risk Factors; Treatment Outcome | 2014 |
Umeclidinium for the treatment of chronic obstructive pulmonary disease.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2014 |
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.
Topics: Benzyl Alcohols; Bromides; Bronchodilator Agents; Chlorobenzenes; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic | 2015 |
Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adult; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2015 |
Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines.
Topics: Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Humans; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2015 |
A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Benzyl Alcohols; Chlorobenzenes; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2015 |
Umeclidinium (Incruse Ellipta) for COPD.
Topics: Administration, Inhalation; Animals; Cholinergic Antagonists; Clinical Trials as Topic; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2015 |
[Are there cardiovascular adverse effects of inhaled anticholinergics?].
Topics: Administration, Inhalation; Bronchodilator Agents; Cardiovascular Diseases; Cardiovascular System; Cholinergic Antagonists; Clinical Trials as Topic; Glycopyrrolate; Humans; Incidence; Ipratropium; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Risk Factors; Scopolamine Derivatives; Tiotropium Bromide | 2015 |
Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
Topics: Aged; Bayes Theorem; Bronchodilator Agents; Drug Administration Schedule; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Lung; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Recovery of Function; Spirometry; Surveys and Questionnaires; Time Factors; Tiotropium Bromide; Treatment Outcome; Tropanes | 2015 |
Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis.
Topics: Administration, Inhalation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Dry Powder Inhalers; Muscarinic Antagonists; Muscle Tonus; Muscle, Smooth; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2016 |
[Current optimization of combined therapy for chronic obstructive pulmonary disease].
Topics: Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Humans; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2015 |
[LAMA/LABA fixed dose combination for treatment of COPD].
Topics: Adrenergic beta-2 Receptor Agonists; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Delayed-Action Preparations; Drug Combinations; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Respiratory Function Tests; Tiotropium Bromide; Treatment Outcome | 2016 |
Umeclidinium Plus Vilanterol Versus Placebo, Umeclidinium, or Vilanterol Monotherapies for Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials.
Topics: Albuterol; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic | 2016 |
Umeclidinium (Incruse Ellipta) for COPD.
Topics: Administration, Inhalation; Bronchodilator Agents; Cholinergic Antagonists; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2017 |
Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Androstadienes; Animals; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Clinical Trials as Topic; Drug Combinations; Glucocorticoids; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Recovery of Function; Research Design; Treatment Outcome | 2017 |
Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors.
Topics: Cholinergic Antagonists; Humans; Myeloid Differentiation Factor 88; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Toll-Like Receptors | 2012 |
55 trial(s) available for quinuclidines and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial.
Topics: Administration, Inhalation; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Humans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines; State Medicine | 2022 |
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Fluticasone; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2022 |
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Salmeterol Xinafoate; Treatment Outcome | 2019 |
The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Disease Progression; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Health Status; Humans; Japan; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Recovery of Function; Time Factors; Treatment Outcome | 2019 |
COPD exacerbation costs in the IMPACT study: a within-trial analysis.
Topics: Administration, Inhalation; Adult; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Female; Fluticasone; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Respiratory Function Tests; Severity of Illness Index | 2020 |
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Topics: Aged; Androstadienes; Benzyl Alcohols; Cardiovascular Diseases; Chlorobenzenes; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2020 |
Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Quinuclidines; Treatment Outcome | 2020 |
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Drug Monitoring; Female; Health Status Disparities; Humans; Male; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Respiratory Function Tests; Respiratory System Agents; Symptom Flare Up | 2021 |
A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Benzoxazines; Cross-Over Studies; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Forced Expiratory Volume; Humans; Japan; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Tiotropium Bromide; Treatment Outcome | 2021 |
Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
Topics: Administration, Inhalation; Androstadienes; Asthma; Benzyl Alcohols; Bromides; Chlorobenzenes; Double-Blind Method; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2021 |
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Budesonide; Chlorobenzenes; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Forced Expiratory Volume; Formoterol Fumarate; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines | 2017 |
The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
Topics: Adult; Aged; Albuterol; Androstadienes; Asthma; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glucocorticoids; Humans; Male; Middle Aged; Muscarinic Antagonists; Peak Expiratory Flow Rate; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2017 |
Sensory-mechanical effects of a dual bronchodilator and its anticholinergic component in COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Airway Resistance; Albuterol; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cholinergic Antagonists; Cross-Over Studies; Double-Blind Method; Dyspnea; Electromyography; Female; Humans; Inhalation; Male; Plethysmography, Whole Body; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Respiratory Function Tests; Respiratory Muscles; Spirometry | 2018 |
Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
Topics: Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Severity of Illness Index | 2017 |
Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
Topics: Administration, Inhalation; Adult; Benzyl Alcohols; Bronchodilator Agents; Budesonide, Formoterol Fumarate Drug Combination; Chlorobenzenes; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyspnea; Female; Fluticasone; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Surveys and Questionnaires | 2018 |
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2018 |
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Dyspnea; Female; Glucocorticoids; Hospitalization; Humans; Intention to Treat Analysis; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines | 2018 |
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Female; Humans; Male; Middle Aged; Monte Carlo Method; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Random Allocation | 2018 |
Topics: Adult; Age Factors; Aged; B-Lymphocytes; Benzyl Alcohols; Blood Cells; Bronchodilator Agents; Chlorobenzenes; Cross-Over Studies; Disease Progression; Drug Combinations; Female; Flow Cytometry; Forced Expiratory Volume; Humans; Immunophenotyping; Liver Cirrhosis, Biliary; Lymphocyte Activation; Male; Middle Aged; Pruritus; Pulmonary Disease, Chronic Obstructive; Quinuclidines; T-Lymphocytes, Regulatory; Th17 Cells; Treatment Outcome | 2018 |
Topics: Adult; Aged; Benzyl Alcohols; Chlorobenzenes; Disease Progression; Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Switzerland | 2018 |
Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
Topics: Aged; Benzoxazines; Benzyl Alcohols; Chlorobenzenes; Cost-Benefit Analysis; Cross-Over Studies; Drug Combinations; Female; Humans; Male; Middle Aged; National Health Programs; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Single-Blind Method; Spain; Tiotropium Bromide | 2018 |
Effect of triple therapy in patients with asthma-COPD overlap
.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Androstadienes; Asthma; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cross-Over Studies; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Forced Expiratory Volume; Humans; Japan; Male; Middle Aged; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2019 |
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Therapy, Combination; Eosinophils; Female; Humans; Male; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2019 |
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Aged; Androstadienes; Anticonvulsants; Benzyl Alcohols; Bromides; Chlorobenzenes; Drug Combinations; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Predictive Value of Tests; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2020 |
Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.
Topics: Administration, Oral; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Benzyl Alcohols; Chlorobenzenes; Drug Combinations; Dry Powder Inhalers; Female; Heart Rate; Humans; Male; Middle Aged; Muscarinic Antagonists; Potassium; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Vasodilator Agents; Verapamil; Young Adult | 2013 |
Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
Topics: Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Severity of Illness Index; Treatment Outcome; Vital Capacity | 2013 |
Umeclidinium in patients with COPD: a randomised, placebo-controlled study.
Topics: Administration, Inhalation; Aged; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Smoking; Treatment Outcome | 2014 |
Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.
Topics: Administration, Inhalation; Adult; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Dry Powder Inhalers; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Treatment Outcome | 2014 |
Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study.
Topics: Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2014 |
Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies.
Topics: Administration, Inhalation; Adult; Bronchial Spasm; Bronchodilator Agents; Double-Blind Method; Female; Humans; Male; Muscarinic Antagonists; Piperidines; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Retrospective Studies; Young Adult | 2014 |
Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
Topics: Administration, Inhalation; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Scopolamine Derivatives; Time Factors; Tiotropium Bromide; Treatment Outcome | 2014 |
Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Aged; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Scopolamine Derivatives; Tiotropium Bromide | 2014 |
Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study.
Topics: Aged; Benzyl Alcohols; Chlorobenzenes; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2014 |
Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials.
Topics: Benzyl Alcohols; Chlorobenzenes; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2014 |
Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
Topics: Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2014 |
Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
Topics: Administration, Inhalation; Adult; Benzyl Alcohols; China; Chlorobenzenes; Cross-Over Studies; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Young Adult | 2015 |
Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Androstadienes; Benzyl Alcohols; Chlorobenzenes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glucocorticoids; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Vital Capacity | 2015 |
Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial.
Topics: Administration, Inhalation; Adult; Bronchodilator Agents; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2015 |
Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Eosinophils; Female; Forced Expiratory Volume; Humans; Leukocyte Count; Male; Middle Aged; Muscarinic Antagonists; Predictive Value of Tests; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Treatment Outcome | 2015 |
Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Asian People; Benzyl Alcohols; Bronchodilator Agents; China; Chlorobenzenes; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Recovery of Function; Time Factors; Treatment Outcome; Vital Capacity | 2015 |
Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.
Topics: Administration, Inhalation; Aged; Albuterol; Bronchodilator Agents; Double-Blind Method; Drug Therapy, Combination; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome; Vital Capacity | 2016 |
Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Benzyl Alcohols; Chlorobenzenes; Cross-Over Studies; Drug Combinations; Female; Fluoroquinolones; Healthy Volunteers; Humans; Male; Middle Aged; Moxifloxacin; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Tablets; Topoisomerase II Inhibitors; Young Adult | 2016 |
Long-term (52 weeks) safety and tolerability of umeclidinium in Japanese patients with chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Aged; Drug Administration Schedule; Dry Powder Inhalers; Female; Humans; Japan; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2016 |
Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2016 |
Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Tiotropium Bromide; Treatment Outcome | 2016 |
A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD.
Topics: Cholinergic Antagonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Tiotropium Bromide; Treatment Outcome | 2016 |
A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Europe; Female; Forced Expiratory Volume; Humans; Intention to Treat Analysis; Lung; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Recovery of Function; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome; United States | 2016 |
The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Male; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2016 |
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenotype; Practice Guidelines as Topic; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2016 |
Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Tiotropium Bromide; Treatment Outcome | 2017 |
A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD.
Topics: Adult; Aged; Aged, 80 and over; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome; Vital Capacity | 2012 |
28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Area Under Curve; Benzyl Alcohols; Chlorobenzenes; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Severity of Illness Index; Time Factors; Treatment Outcome | 2012 |
Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients.
Topics: Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Lung Volume Measurements; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Retrospective Studies; Spirometry | 2013 |
Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Piperidines; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Receptor, Muscarinic M3; Scopolamine Derivatives; Tiotropium Bromide | 2013 |
Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies.
Topics: Administration, Inhalation; Aged; Drug Administration Schedule; Female; Heart Rate; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Safety | 2013 |
50 other study(ies) available for quinuclidines and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model.
Topics: Administration, Inhalation; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cost-Benefit Analysis; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Salmeterol Xinafoate; Treatment Outcome; United Kingdom | 2021 |
Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system.
Topics: Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chile; Chlorobenzenes; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Fluticasone; Forced Expiratory Volume; Humans; Public Health; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2022 |
Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study.
Topics: Administration, Inhalation; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Humans; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Retrospective Studies | 2022 |
A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD.
Topics: Administration, Inhalation; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Humans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2022 |
Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
Topics: Adrenergic beta-2 Receptor Agonists; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Retrospective Studies; Taiwan; Tiotropium Bromide; Treatment Outcome | 2022 |
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial.
Topics: Administration, Inhalation; Androstadienes; Bayes Theorem; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Delivery of Health Care; Double-Blind Method; Drug Combinations; Fluticasone; Humans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2022 |
[Experience of using a triple fixed combination in the treatment of patients with chronic obstructive pulmonary disease].
Topics: Administration, Inhalation; Benzyl Alcohols; Bromides; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Treatment Outcome | 2022 |
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Female; Fluticasone; Humans; Male; Patient Acceptance of Health Care; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Retrospective Studies | 2023 |
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History.
Topics: Administration, Inhalation; Adult; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Fluticasone; Humans; Patient Acceptance of Health Care; Pneumonia; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Tiotropium Bromide | 2023 |
Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Chlorobenzenes; Humans; Muscarinic Antagonists; Primary Health Care; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Retrospective Studies | 2023 |
Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
Topics: Administration, Inhalation; Adult; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Drug Prescriptions; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Retrospective Studies; Tiotropium Bromide; Treatment Outcome | 2023 |
Changes in Oral Corticosteroid Utilization in Patients with COPD Following Initiation of FF/UMEC/VI.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Female; Fluticasone; Humans; Male; Medicare; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Retrospective Studies; United States | 2023 |
Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Canada; Chlorobenzenes; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Disease Progression; Drug Combinations; Drug Costs; Female; Humans; Lung; Male; Models, Economic; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quality-Adjusted Life Years; Quinuclidines; Recovery of Function; Time Factors; Treatment Outcome | 2019 |
Fixed Triple Therapy in Chronic Obstructive Pulmonary Disease and Survival. Living Better, Longer, or Both?
Topics: Androstadienes; Benzyl Alcohols; Chlorobenzenes; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2020 |
Mortality in IMPACT: Confounded by Asthma?
Topics: Androstadienes; Asthma; Benzyl Alcohols; Chlorobenzenes; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2020 |
Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?
Topics: Androstadienes; Asthma; Benzyl Alcohols; Chlorobenzenes; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2020 |
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Surveys and Questionnaires | 2020 |
Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cross-Sectional Studies; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Humans; Medicare Part C; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome; United States | 2020 |
Reply to López-Campos
Topics: Androstadienes; Benzyl Alcohols; Chlorobenzenes; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2021 |
Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Benzyl Alcohols; Budesonide, Formoterol Fumarate Drug Combination; Chlorobenzenes; Cohort Studies; Comparative Effectiveness Research; Disease Progression; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pneumonia; Propensity Score; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines | 2021 |
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial.
Topics: Administration, Inhalation; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Forced Expiratory Volume; Humans; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2021 |
Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Databases, Factual; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Propensity Score; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Retrospective Studies; Time-to-Treatment; Tiotropium Bromide; United States | 2021 |
Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial.
Topics: Administration, Inhalation; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Smokers; Treatment Outcome | 2021 |
Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Humans; Markov Chains; Models, Economic; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinuclidines; Severity of Illness Index; Time Factors; Tiotropium Bromide; Treatment Outcome | 2017 |
Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cholinergic Antagonists; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Fluticasone; Humans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines | 2018 |
Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Benzyl Alcohols; Chlorobenzenes; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Retrospective Studies; Tiotropium Bromide; Treatment Outcome | 2018 |
Trelegy Ellipta--a three-drug inhaler for COPD.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Drug Interactions; Humans; Lung; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2018 |
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β
Topics: Aged; Benzyl Alcohols; Chlorobenzenes; Disease Progression; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Respiratory System Agents; Secondary Prevention; Symptom Assessment; Treatment Outcome | 2018 |
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective.
Topics: Adrenergic beta-2 Receptor Agonists; Androstadienes; Cost-Benefit Analysis; Delayed-Action Preparations; Disease Progression; Drug Therapy, Combination; Female; Fluticasone; Humans; Maintenance Chemotherapy; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2018 |
[IMPACT study in COPD].
Topics: Androstadienes; Benzyl Alcohols; Chlorobenzenes; Clinical Trials, Phase III as Topic; Drug Combinations; Glucocorticoids; Humans; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic | 2019 |
Umeclidinium-vilanterol inhaler approved for COPD.
Topics: Administration, Inhalation; Benzyl Alcohols; Chlorobenzenes; Drug Approval; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; United States; United States Food and Drug Administration | 2014 |
Umeclidinium/Vilanterol: first global approval.
Topics: Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Chlorobenzenes; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Interactions; Forced Expiratory Volume; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2014 |
Umeclidinium/vilanterol fixed-dose combination for COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Animals; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Delayed-Action Preparations; Drug Combinations; Dry Powder Inhalers; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; United States; United States Food and Drug Administration | 2014 |
Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Area Under Curve; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Clinical Trials, Phase III as Topic; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Models, Biological; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic | 2014 |
Wanted: new treatments for COPD.
Topics: Benzyl Alcohols; Chlorobenzenes; Female; Humans; Male; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Scopolamine Derivatives; Tiotropium Bromide | 2014 |
[Once daily with a powder inhaler].
Topics: Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Dry Powder Inhalers; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2015 |
▼Umeclidinium: another LAMA for COPD.
Topics: Adult; Delayed-Action Preparations; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; United Kingdom | 2015 |
In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Topics: Administration, Inhalation; Aerosols; Androstadienes; Asthma; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Clinical Trials as Topic; Drug Combinations; Drug Delivery Systems; Dry Powder Inhalers; Equipment Design; Humans; Inhalation; Lung; Models, Anatomic; Models, Biological; Powders; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Severity of Illness Index | 2015 |
Review: Combination umeclidinium/vilanterol improved health status more than umeclidinium in COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Chlorobenzenes; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2015 |
Safety of long acting muscarinic antagonists: are all these drugs always and equally safe?
Topics: Administration, Inhalation; Bronchodilator Agents; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2016 |
Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients.
Topics: Administration, Inhalation; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cost-Benefit Analysis; Drug Combinations; Female; Forced Expiratory Volume; Humans; Longitudinal Studies; Male; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinuclidines; Severity of Illness Index; Spain; Symptom Assessment; Tiotropium Bromide; Treatment Outcome | 2016 |
[Fixed combination of long-acting bronchodilators in COPD].
Topics: Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Chlorobenzenes; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2015 |
Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Clinical Trials as Topic; Drug Combinations; Female; Forced Expiratory Volume; Genome-Wide Association Study; HLA Antigens; Humans; Male; Middle Aged; Muscarinic Antagonists; Pharmacogenetics; Polymorphism, Single Nucleotide; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome; Vital Capacity | 2016 |
Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Benzyl Alcohols; Chlorobenzenes; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Combinations; Female; Forced Expiratory Volume; Health Status; Humans; Lung; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Phenethylamines; Propylamines; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Retrospective Studies; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2016 |
Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials.
Topics: Administration, Inhalation; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Combinations; Dry Powder Inhalers; Equipment Design; Health Knowledge, Attitudes, Practice; Humans; Lung; Muscarinic Antagonists; Patient Compliance; Patient Education as Topic; Patient Preference; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2016 |
Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Cardiovascular Diseases; Chlorobenzenes; Comorbidity; Drug Combinations; Evidence-Based Medicine; Humans; Lung; Muscarinic Antagonists; Patient Safety; Patient Selection; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Time Factors; Tiotropium Bromide; Treatment Outcome | 2016 |
Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)ace
Topics: Administration, Inhalation; Animals; Bronchial Spasm; CHO Cells; Cricetinae; Cricetulus; Drug Stability; Esters; Guinea Pigs; Humans; Male; Mice; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quaternary Ammonium Compounds; Quinuclidines; Radioligand Assay; Receptor, Muscarinic M3; Stereoisomerism; Structure-Activity Relationship; Tropanes | 2009 |
The discovery of AZD9164, a novel muscarinic M3 antagonist.
Topics: Blood Proteins; Drug Evaluation, Preclinical; Humans; Muscarinic Antagonists; Piperidines; Protein Binding; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Receptor, Muscarinic M3; Structure-Activity Relationship | 2011 |
Alkyne-quinuclidine derivatives as potent and selective muscarinic antagonists for the treatment of COPD.
Topics: Alkynes; Cholinergic Antagonists; Molecular Structure; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Receptor, Muscarinic M2; Receptor, Muscarinic M3; Structure-Activity Relationship | 2008 |